🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Running a psychiatric practice shouldn't feel like you have to figure it out alone. Stop scrolling through disorganized Facebook groups and listservs for answers. The Osmind Psychiatry Collective connects you with 1000+ forward-thinking clinicians solving real practice

📱 Evidence-Based Care for MDD Through Smartphones "Rejoyn is a convenient, adjunctive treatment option that is accessed through the patient's smartphone." Adjunctive treatment where patients already are. Rejoyn delivers structured therapeutic content through smartphones,

We are excited to announce a partnership with CybinInc, a clinical-stage neuropsychiatry company developing next-generation mental health treatment options. "Through this partnership, we are aligning incentives across stakeholders to help patients in need," says Jimmy Qian,

💪 "It's like going to the gym, but it's your brain going to the gym... It's a bit like working out your biceps." Neuroplasticity in action: Rejoyn applies strength-training principles to brain circuits. Like muscles that strengthen through repeated exercise,

Rejoyn—the first FDA-authorized prescription digital therapeutic for MDD symptoms—delivers evidence-based treatment directly through patients’ smartphones. In our latest webinar, Dr. Rakesh Jain explores how this adjunctive therapy, designed to target neural circuits that may be

DSM-5-TR Cross-Cutting Measure: Real-world data coming to hashtag#APA2025 📊 Our team will present findings on how the DSM-5-TR Cross-Cutting Measure performs across 126 U.S. psychiatric practices at this year's American Psychiatric Association annual meeting. We integrated the

TMS typically requires dedicated space, $100K+ equipment, and 36 days of treatment. Join Dr. William Sauvé, MD, Chief Medical Officer at Osmind, and Dr. Don Vaughn, Ph.D., CEO of Ampa, on Wednesday, May 28th at 11 am PT / 2 PM ET to discover a mobile alternative that fits in two

📊 Promising early results: 70% remission and 90% response rates observed after just one day of treatment. Join Dr. William Sauvé, MD, Chief Medical Officer at Osmind, and Dr. Don Vaughn, Ph.D., CEO of Ampa, on Wednesday, May 28th at 11 am PT / 2 PM ET to see how you can use

Happening tomorrow: Join our regular, live Psychiatry Collective event at 11 am PT / 2 pm ET 🧠 Connect with clinical experts like Brittany Albright MD, MPH, Carlene MacMillan, MD, FCTMSS,DFAACAP, William Sauvé, MD, and other forward-thinking clinicians for an informal live

Osmind enjoyed connecting with everyone at the American Psychiatric Association Annual Meeting! (American Psychiatric Association) Our team was in full force sharing insights on advancing psychiatric care: •Presented on "Navigating Clinical and Administrative Domains in Changing Times,"

⏰ FINAL DAY to register! Tomorrow, Dr. William Sauvé, MD, Chief Medical Officer at Osmind, and Dr. Don Vaughn, Ph.D., CEO of Ampa, show you how to treat 3x more patients with mobile TMS while achieving higher remission rates. Learn implementation strategies for multi-use

📊 Psychiatry practices lose tens of thousands annually with the wrong billing services… We put together a downloadable guide to help you make the right choice (linked below). The stark reality: General medical billers simply don't understand the complexities of psychiatric

We are excited to announce three strategic leadership appointments to simplify how psychiatric practices manage operations and deliver care. Adrian Vera joins as chief technology officer, bringing over a decade of healthcare technology leadership from scaling Aluna's FDA-cleared